Arbutus Biopharma (ABUS) Stock Price, Quote, News & History | Benzinga

SPY778.66+0.01%QQQ751.270.00%BTC/USD82,328.97+0.78%DIA516.22+0.02%GLD384.57−0.00%TLT77.90−0.10%

Arbutus Biopharma Corp (ABUS) Stock Price, Quote, News & History

ABUSNASDAQ

Trade with Public

Trade with Public

$4.22

0.040.96%

Last update: Oct 9, 4:00 PM

$4.22

0.040.96%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$4.17

Close

$4.22

Volume / Avg.

3.15M / 4.66M

Day Range

$4.13 - $4.27

52 Wk Range

3.50 - 5.45

Market Cap

$836.01M

P/E Ratio

5.29

Dividend Yield

-

Exchange

NASDAQ

RSI

34

Short Interest

13.86%

Days to Cover

5.01

Recent Arbutus Biopharma Corp News

Why Is Arbutus Biopharma Stock Gaining Friday?

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.

Vandana Singh

Europe Clears First Flu/COVID Combo Shot From Moderna

Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.

Vandana Singh

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopharma among other stocks also falling.

Avi Kapoor

Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estimates. Gainers include CTNT, MYSE, WNW, MDCX, WSHP, MAMO, ALIT, HQ, and SLDP while XHG and BIRD were among the losers.

Avi Kapoor

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor concerns and clearing legal uncertainty.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-24.63M

Investing Cash Flow (TTM)

-10.84M

Financing Cash Flow (TTM)

17.25M

Free Cash Flow (TTM)

-24.63M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-18.22M

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$735.97M

PE Ratio (TTM)

5.29

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.47

PB Ratio (TTM)

3.20

Earnings Yield % (TTM)

18.90%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

4.80

Price / EBITDA (TTM)

5.31

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.31

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$19.17M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-